Targeting an MDM2/MYC Axis to Overcome Drug Resistance in Multiple Myeloma.

Omar FaruqDavidson ZhaoMariusz ShresthaAndrea VecchioneEldad ZacksenhausHong Chang

Published in: Cancers (2022)

Our findings provide a rationale for the therapeutic targeting of MDM2/c-Myc axis to improve clinical outcome of patients with refractory/relapsed MM.

Keyphrases

multiple myeloma
cancer therapy
acute lymphoblastic leukemia
acute myeloid leukemia
diffuse large b cell lymphoma
clinical trial
transcription factor
drug delivery